Inclusion of the Symbol Digit Modalities Test in a revised assessment of ‘no evidence of disease activity-4 (NEDA-4)’ in Latin-American patients with multiple sclerosis-Reference-Cited by-同舟云学术

Inclusion of the Symbol Digit Modalities Test in a revised assessment of ‘no evidence of disease activity-4 (NEDA-4)’ in Latin-American patients with multiple sclerosis

Published:2020-07 Issue: Volume:42 Page:102076
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Guevara Carlos,Villa Eduardo,Diaz Violeta,Garrido Cristian,Martinez Melissa,Orellana Patricia,Alarcón Pablo,Silva-Rosas Carlos,Barker Gareth J,Kempton Matthew J,de Grazia José

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference49 articles.

1. Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates;Anderson;J. Neurol.,2007

2. Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian consensus recommendations;Arnold;Mult. Scler. J. Exp. Transl. Clin.,2015

3. Manifestations of early brain recovery associated with abstinence from alcoholism;Bartsch;Brain,2007

4. Evaluating and reducing the impact of white matter lesions on brain volume measurements;Battaglini;Hum. Brain Mapp.,2012

5. Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis;Benedict;Mult. Scler.,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification and management of subclinical disease activity in early multiple sclerosis: a review;Journal of Neurology;2023-10-21

2. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review];Neurology and Therapy;2023-10-11

3. Current Status of Oral Disease-Modifying Treatment Effects on Cognitive Outcomes in Multiple Sclerosis: A Scoping Review;Bioengineering;2023-07-18

4. Early first‐line treatment response and subsequent disability worsening in relapsing–remitting multiple sclerosis;European Journal of Neurology;2021-12-26

5. Identifying Early Neuropsychological Indicators of Cognitive Involvement in Multiple Sclerosis;Neuropsychiatric Disease and Treatment;2021-02